Management of malignant ventricular arrhythmia--experience with lorcainide

Area of Science:

• Cardiology
• Pharmacology

Background:

• Sudden cardiac death (SCD) remains a significant health concern.
• Ventricular tachycardia (VT) salvos are a key risk factor for SCD in patients with coronary disease or cardiomyopathy.
• Effective antiarrhythmic drug selection is crucial for preventing SCD.

Purpose of the Study:

• To develop and evaluate a systematic approach for selecting antiarrhythmic drugs.
• To assess the efficacy of individualized drug therapy in preventing recurrent life-threatening ventricular arrhythmias.

Main Methods:

• A 4-phase drug selection strategy was implemented: control period, acute drug testing, short-term efficacy and tolerance evaluation, and long-term therapy.
• Seventy-six patients with ventricular arrhythmias underwent drug testing.
• Lorcainide was selected for long-term therapy in 15 patients.

Main Results:

• The systematic approach facilitated the identification of effective and well-tolerated antiarrhythmic agents.
• In patients receiving long-term lorcainide, only 1 sudden death occurred over a 23-month follow-up period.
• Individualized drug therapy demonstrated significant protection against recurrent life-threatening ventricular arrhythmias.

Conclusions:

• A systematic, phased approach to antiarrhythmic drug selection is effective for managing patients at risk of sudden cardiac death.
• Individualized therapy based on objective drug testing improves outcomes in patients with ventricular arrhythmias.
• This strategy offers a promising method for preventing sudden cardiac death in high-risk populations.